PHARMACOKINETICS OF PHENYTOIN IN HYPERLIPIDEMIA

The study was performed on 48 subjects divided into four groups: contr ol (1), hypercholesterolemia (2), hypertriglyceridemia (3) and mixed h yperlipidemia (4). The concentration and pharmacokinetic parameters fo r total phenytoin were determined after a single oral dose of 300 mg. Hypercholesterolemia (HCh) and mixed hyperlipidemia (MI-IL) significan tly influenced the pharmacokinetics of total phenytoin, while hypertri glyceridemia (HTG) was without effect. The mean serum concentration of phenytoin was significantly higher in the HCh and MHL groups as compa red with the control from 12 to 72 h. A significant increase in AUC, a nd t(max) was observed in the HCh group. No significant changes were f ound in the HTG group. In the MHL group, AUC increased and CL/F/BW dec reased. It was shown that hypercholesterolemia and mixed hyperlipidemi a change the pharmacokinetics of phenytoin.